How can digital health applications (DiGA) be successfully integrated into everyday healthcare? One year after the BfArM’s provisional listing of the ADHD application ORIKO, Daria Radant, a member of the executive board and Head of Neuroscience at Takeda Germany, takes stock on the Forward Pharma Podcast.
As a digital architect, she explores the tension between technical innovation, regulatory requirements, and real-world care processes. The interview addresses practical hurdles such as the authorization process for e-prescriptions, the importance of co-creation and user feedback, and the need for a reliable regulatory framework to sustainably establish digital therapies within the healthcare system.
For Radant, one thing is very clear:
A sustainable digital health solution does not emerge from a sales silo: Only early-stage co-creation among pharmaceutical companies, startups, and the experiences of those affected can create genuine therapeutic value.
The ORIKO ADHD therapy was developed by a team of experts from the University Medical Center Hamburg-Eppendorf, MINDNET E-Health AG, and ADHD experts from Germany, and is distributed by Takeda Pharma GmbH.
Comprix
Long-term ranking
TOP 3
Member of the GWA - Germany's
leading agencies
